Skip to main content
Caplight Logo









CytoImmune Therapeutics

CytoImmune Therapeutics

Private
Duarte, CaliforniaHealthcare & Life Scienceshttps://www.cytoimmune.com/

Last Round

Series A

Aug 6, 2021

Total Funding Raised

$36M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

CytoImmune Therapeutics is a clinical-stage biotechnology company that develops engineered natural killer (NK) cell-based cancer immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

natural killer cell therapyNK cell therapyallogeneic cell therapyoff-the-shelf cell therapycontract development and manufacturing organizationCDMOcell therapy manufacturingCAR-NKbiopharmaceutical manufacturingclinical-stage biotechoncology therapeuticsimmunotherapyGMP manufacturingbiotech services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CytoImmune Therapeutics Comparables

Compare CytoImmune Therapeutics with similar companies based on industry and business-model similarity.

CytoImmune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ONK Therapeutics
87%
Shoreline Biosciences
86%
Artiva
78%

CytoImmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 6, 2021

Key People

Founding team and executive leadership

Jose Eduardo Vidal

Chief Executive Officer

Executive Team

CytoImmune Therapeutics Investors

Notable investors and investment history

CytoImmune Therapeutics investors
InvestorRounds
Sofinnova PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors grew 89% MoM.

  • Apr 4, 2026

    Monthly visitors increased 832% MoM.

CytoImmune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CytoImmune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CytoImmune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDuarte, California
Employee Range16
Year Founded2017
Last FundingAug 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?